These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26806303)

  • 1. Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases.
    Liu R; Proud CG
    Acta Pharmacol Sin; 2016 Mar; 37(3):285-94. PubMed ID: 26806303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eukaryotic Elongation Factor 2 Kinase a Pharmacological Target to Regulate Protein Translation Dysfunction in Neurological Diseases.
    Beretta S; Gritti L; Verpelli C; Sala C
    Neuroscience; 2020 Oct; 445():42-49. PubMed ID: 32088293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eukaryotic elongation factor-2 kinase (eEF2K): a potential therapeutic target in cancer.
    Fu LL; Xie T; Zhang SY; Liu B
    Apoptosis; 2014 Oct; 19(10):1527-31. PubMed ID: 25023961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy.
    Wang H; Jin W; Li Z; Guo C; Zhang L; Fu L
    Drug Discov Today; 2024 Oct; 29(10):104155. PubMed ID: 39214495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target.
    Karakas D; Ozpolat B
    J Mol Med (Berl); 2020 Jun; 98(6):775-787. PubMed ID: 32377852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer.
    Zhu S; Liao M; Tan H; Zhu L; Chen Y; He G; Liu B
    J Med Chem; 2021 Jul; 64(13):8870-8883. PubMed ID: 34162208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.
    Zhang B; Zou J; Zhang Q; Wang Z; Wang N; He S; Zhao Y; Naman CB
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity.
    Wang X; Xie J; da Mota SR; Moore CE; Proud CG
    Biochem J; 2015 Apr; 467(2):321-31. PubMed ID: 25670349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Eukaryotic elongation factor 2 kinase and cancer].
    Wang GZ; Qi X; Li J
    Yao Xue Xue Bao; 2015 Jul; 50(7):808-13. PubMed ID: 26552140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles.
    Kenney JW; Moore CE; Wang X; Proud CG
    Adv Biol Regul; 2014 May; 55():15-27. PubMed ID: 24853390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and indirect activation of eukaryotic elongation factor 2 kinase by AMP-activated protein kinase.
    Johanns M; Pyr Dit Ruys S; Houddane A; Vertommen D; Herinckx G; Hue L; Proud CG; Rider MH
    Cell Signal; 2017 Aug; 36():212-221. PubMed ID: 28502587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies.
    Onder FC; Durdagi S; Kahraman N; Uslu TN; Kandemir H; Atici EB; Ozpolat B; Ay M
    Bioorg Chem; 2021 Nov; 116():105296. PubMed ID: 34488125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and structure-activity relationship of a focused library of β-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer.
    Guo Y; Zhao Y; Wang G; Chen Y; Jiang Y; Ouyang L; Liu B
    Eur J Med Chem; 2018 Jan; 143():402-418. PubMed ID: 29202403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanism for the Control of Eukaryotic Elongation Factor 2 Kinase by pH: Role in Cancer Cell Survival.
    Xie J; Mikolajek H; Pigott CR; Hooper KJ; Mellows T; Moore CE; Mohammed H; Werner JM; Thomas GJ; Proud CG
    Mol Cell Biol; 2015 May; 35(10):1805-24. PubMed ID: 25776553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation and roles of elongation factor 2 kinase.
    Proud CG
    Biochem Soc Trans; 2015 Jun; 43(3):328-32. PubMed ID: 26009171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells.
    Zhu H; Yang X; Liu J; Zhou L; Zhang C; Xu L; Qin Q; Zhan L; Lu J; Cheng H; Sun X
    Cell Stress Chaperones; 2015 Mar; 20(2):217-20. PubMed ID: 25248493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of new substrates of the elongation factor-2 kinase suggests a broader role in the cellular nutrient response.
    Lazarus MB; Levin RS; Shokat KM
    Cell Signal; 2017 Jan; 29():78-83. PubMed ID: 27760376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy.
    Moore CE; Wang X; Xie J; Pickford J; Barron J; Regufe da Mota S; Versele M; Proud CG
    Cell Signal; 2016 Apr; 28(4):284-93. PubMed ID: 26795954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling.
    Wang X; Regufe da Mota S; Liu R; Moore CE; Xie J; Lanucara F; Agarwala U; Pyr Dit Ruys S; Vertommen D; Rider MH; Eyers CE; Proud CG
    Mol Cell Biol; 2014 Nov; 34(22):4088-103. PubMed ID: 25182533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elongation Factor 2 Kinase Is Regulated by Proline Hydroxylation and Protects Cells during Hypoxia.
    Moore CE; Mikolajek H; Regufe da Mota S; Wang X; Kenney JW; Werner JM; Proud CG
    Mol Cell Biol; 2015 May; 35(10):1788-804. PubMed ID: 25755286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.